NASDAQ:EPZM

Epizyme Stock Forecast, Price & News

$8.23

+0.01 (+0.12 %)

(As of 04/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$8.15

Now: $8.23▼

$8.45

50-Day Range

$7.45

MA: $8.84▼

$10.19

52-Week Range

$7.44

Now: $8.23▼

$22.00

Volume827,453 shs

Average Volume1.10 million shs

Market Capitalization$837.69 million

P/E RatioN/A

Dividend YieldN/A

Beta1.76

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:EPZM

Previous Symbol

CUSIPN/A

CIK1571498

Webwww.epizyme.com

Phone617-229-5872

Employees304

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.33

Current Ratio8.95

Quick Ratio8.71

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$23.80 million

Price / Sales35.20

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.22 per share

Price / Book2.56

Profitability

EPS (Most Recent Fiscal Year)($1.93)

Net Income$-170,290,000.00

Net Margins-1,899.35%

Return on Equity-83.45%

Return on Assets-52.66%

Miscellaneous

Outstanding Shares101,785,000

Market Cap$837.69 million

Next Earnings Date5/3/2021 (Estimated)

OptionableOptionable

Headlines

Epizyme, Inc. (NASDAQ:EPZM) Receives Consensus Rating of "Buy" from Analysts
April 10, 2021 | americanbankingnews.com

Epizyme, Inc. (NASDAQ:EPZM) Insider Jeffery Kutok Sells 2,029 Shares
April 7, 2021 | americanbankingnews.com

Epizyme (NASDAQ:EPZM) Stock Price Down 5%
April 6, 2021 | americanbankingnews.com

Epizyme (NASDAQ:EPZM) Trading Up 6.6%
April 5, 2021 | americanbankingnews.com

$7.20 Million in Sales Expected for Epizyme, Inc. (NASDAQ:EPZM) This Quarter
April 3, 2021 | americanbankingnews.com

2 “Strong Buy” Stocks Insiders Are Snapping Up - Nasdaq
April 1, 2021 | nasdaq.com

Epizyme, Inc. (NASDAQ:EPZM) Expected to Announce Earnings of -$0.64 Per Share
April 1, 2021 | americanbankingnews.com

Epizyme Comeback Is Likely, Price Makes It A Buy - Seeking Alpha
March 30, 2021 | seekingalpha.com

Epizyme (NASDAQ:EPZM) Coverage Initiated at Credit Suisse Group
March 30, 2021 | americanbankingnews.com

Epizyme (NASDAQ:EPZM) Trading Up 5% Following Insider Buying Activity
March 30, 2021 | americanbankingnews.com

David M. Mott Buys 28,231 Shares of Epizyme, Inc. (NASDAQ:EPZM) Stock
March 29, 2021 | americanbankingnews.com

Epizyme, Inc. (NASDAQ:EPZM) CEO Sells $81,074.80 in Stock
March 29, 2021 | americanbankingnews.com

The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs - Benzinga
March 26, 2021 | benzinga.com

EPZM Aug 2021 20.000 call
March 25, 2021 | sg.finance.yahoo.com

Epizyme (EPZM) Down 22.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
March 25, 2021 | finance.yahoo.com

Epizyme (EPZM) Down 22.9% Since Last Earnings Report: Can It Rebound?
March 25, 2021 | finance.yahoo.com

Epizyme (NASDAQ:EPZM) Reaches New 52-Week Low at $7.80
March 25, 2021 | americanbankingnews.com

Aura Biosciences Expands Executive Leadership Team with the Appointment of Mark De Rosch, Ph.D., as Chief Operating Officer - StreetInsider.com
March 25, 2021 | streetinsider.com

EPZM May 2021 15.000 put
March 22, 2021 | sg.finance.yahoo.com

EPZM May 2021 15.000 call
March 21, 2021 | sg.finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.83 out of 5 stars

Medical Sector

128th out of 2,021 stocks

Pharmaceutical Preparations Industry

51st out of 772 stocks

3.2 Analyst's Opinion

Consensus Rating
Epizyme has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.00, Epizyme has a forecasted upside of 106.6% from its current price of $8.23.
Amount of Analyst Coverage
Epizyme has only been the subject of 4 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Epizyme has received 473 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Epizyme has received 376 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Epizyme has received 55.71% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote “Outperform” if you believe EPZM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Epizyme does not currently pay a dividend.
Dividend Growth
Epizyme does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Epizyme insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $225,283.00 in company stock and sold $266,862.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.
Percentage Held by Insiders
Only 16.30% of the stock of Epizyme is held by insiders.
Percentage Held by Institutions
89.82% of the stock of Epizyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Epizyme are expected to grow in the coming year, from ($2.23) to ($2.13) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Epizyme is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Epizyme is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Epizyme has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$8.23

+0.01 (+0.12 %)

(As of 04/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

Epizyme (NASDAQ:EPZM) Frequently Asked Questions

Is Epizyme a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Epizyme stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EPZM, but not buy additional shares or sell existing shares.
View analyst ratings for Epizyme or view top-rated stocks.

What stocks does MarketBeat like better than Epizyme?

Wall Street analysts have given Epizyme a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Epizyme wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Epizyme's next earnings date?

Epizyme is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for Epizyme.

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) issued its quarterly earnings data on Monday, February, 22nd. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.06. The biopharmaceutical company earned $8.38 billion during the quarter, compared to analysts' expectations of $6.55 million. Epizyme had a negative net margin of 1,899.35% and a negative trailing twelve-month return on equity of 83.45%. The business's revenue for the quarter was up 95.0% compared to the same quarter last year.
View Epizyme's earnings history.

How has Epizyme's stock price been impacted by Coronavirus (COVID-19)?

Epizyme's stock was trading at $18.46 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EPZM shares have decreased by 55.4% and is now trading at $8.23.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for EPZM?

7 equities research analysts have issued 12 month price objectives for Epizyme's shares. Their forecasts range from $13.00 to $27.00. On average, they expect Epizyme's stock price to reach $17.00 in the next year. This suggests a possible upside of 106.6% from the stock's current price.
View analysts' price targets for Epizyme or view top-rated stocks among Wall Street analysts.

Who are Epizyme's key executives?

Epizyme's management team includes the following people:

Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 53, Pay $1.01M)
Mr. Paolo Tombesi, Chief Financial Officer (Age 57, Pay $628.41k)
Mr. Matthew E. Ros, Exec. VP and Chief Strategy & Bus. Officer (Age 54, Pay $644.06k)
Dr. Shefali Agarwal M.D., MPH, Exec. VP and Chief Medical & Devel. Officer (Age 47, Pay $737.27k)
Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 40)
Dr. Jeffery L. Kutok, Chief Scientific Officer (Age 54)
Jason Fredette, VP of Investor Relations
Mr. John F. Weidenbruch, Gen. Counsel (Age 60)

Who are some of Epizyme's key competitors?

Some companies that are related to Epizyme include Reata Pharmaceuticals (RETA), InnovAge (INNV), ChemoCentryx (CCXI), Karuna Therapeutics (KRTX), Alkermes (ALKS), Arvinas (ARVN), MorphoSys (MOR), Viela Bio (VIE), Pacira BioSciences (PCRX), OPKO Health (OPK), Organogenesis (ORGO), Taro Pharmaceutical Industries (TARO), Amicus Therapeutics (FOLD), Deciphera Pharmaceuticals (DCPH) and Rocket Pharmaceuticals (RCKT).
View all of EPZM's competitors.

What other stocks do shareholders of Epizyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Pfizer (PFE), Micron Technology (MU), Novavax (NVAX), CRISPR Therapeutics (CRSP), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD) and Dynavax Technologies (DVAX).

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $8.23.

How much money does Epizyme make?

Epizyme has a market capitalization of $837.69 million and generates $23.80 million in revenue each year. The biopharmaceutical company earns $-170,290,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Epizyme have?

Epizyme employs 304 workers across the globe.

What is Epizyme's official website?

The official website for Epizyme is www.epizyme.com.

Where are Epizyme's headquarters?

Epizyme is headquartered at 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]

This page was last updated on 4/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here